Kirk A. Frey - Publications

IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B.

Journal: Research square

Published: November 24, 2025

IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B.

Journal: Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents

Published: November 19, 2025

Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration.

Journal: Clinical nuclear medicine

Published: September 19, 2025

The SNMMI Procedure Standard/EANM Practice Guideline for Radionuclide Brain Perfusion Scintigraphy in Suspected Death by Neurologic Criteria (Brain Death) 3.0.

Journal: Journal of nuclear medicine technology

Published: May 27, 2025

Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor: Effectiveness of Dose Reduction and Cycle Delay for Improving Therapy Tolerability.

Journal: Clinical nuclear medicine

Published: May 18, 2025

177Lu-PSMA-617 Single-Photon Emission Computed Tomography/Computed Tomography Dosimetry and Radiobiological Models Demonstrate Decreasing Tumor-to-Kidney Dose Ratio With Successive Cycles.

Journal: International journal of radiation oncology, biology, physics

Published: December 20, 2024

A multicenter longitudinal study of cholinergic subgroups in Parkinson disease.

Journal: Nature communications

Published: October 29, 2024

Case of the Season: 177Lu-DOTATATE Peptide Receptor Radiotherapy With Acute Dialysis Support in a Patient With Chronic Kidney Disease (CKD).

Journal: Seminars in roentgenology

Published: October 01, 2024

Comparison of imaging-based bone marrow dosimetry methodologies and their dose-effect relationships in [177Lu]Lu-PSMA-617 RLT including a novel method with active marrow localization.

Journal: EJNMMI physics

Published: June 18, 2024

Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers.

Journal: Theranostics

Published: May 04, 2024

3-[18F]Fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) PET-A Novel Imaging Modality for Paraganglioma.

Journal: Journal of the Endocrine Society

Published: December 11, 2023

GABAA Receptor Benzodiazepine Binding Sites and Motor Impairments in Parkinson's Disease.

Journal: Brain sciences

Published: November 03, 2023